Japan Lifts Actemra All Case Surveillance Condition
This article was originally published in PharmAsia News
Executive Summary
Japan's Ministry of Health, Labor and Welfare lifted an all-case surveillance requirement for Chugai's Actemra (tocilizumab) for rheumatoid arthritis and polyarticular-course juvenile idiopathic arthritis